- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00682383
Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)
Phase II Trial of Combined Modality Therapy With Growth Factor Support in Locally Advanced NSCLC
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Florida
-
Miami Beach, Florida, Forente stater, 33140
- Mount Sinai Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Histologically or cytologically confirmed NSCLC: Either histologic or cytologic proof of a newly diagnosed non-small cell lung cancer is required. A biopsy with histology is preferred, but cytology is allowed. Histology or cytology from involved mediastinal or supraclavicular lymph nodes alone will be allowed if a separate distal primary lesion is clearly evident on radiographs (i.e., a second biopsy will not be required).
- Patients with two or more parenchymal lesions on same or opposite sides of the lung are ineligible.
- Must have unresectable Stage IIIA (N2) or IIIB disease and also satisfy the following criteria:
Unresectable Stage IIIA (N2) patients:
- N2 mediastinal lymph nodes must be multiple and/or bulky on CT scan or X-ray, such that, in the opinion of the treating investigator, the patient is not a candidate for induction chemotherapy or chemoradiotherapy followed by surgical resection.
- N2 status must be documented by any one of the following methods:
- Histologic or cytologic proof of N2 disease by exploratory thoracotomy, thoracoscopy, mediastinoscopy, mediastinotomy, Wang needle biopsy, fine needle aspiration under bronchoscopic or CT guidance or other method
- Node positivity by PET scan
- Nodes >2 cm on CT scan
- Paralyzed left true vocal cord with separate left lung primary distinct from AP window nodes on CT Scan
- Stage IIIB patients:
- Pathologic documented or radiographically documented positive N3 nodes.
Patients with positive supraclavicular or scalene lymph nodes must not have disease extending up into the cervical region evidenced by one of the following:
- Fine needle aspiration, core needle biopsy or excisional biopsy of supraclavicular N3 nodes
- Biopsy of contralateral mediastinal N3 nodes by mediastinoscopy, mediastinotomy, or thoracotomy
- Fine needle aspiration, core needle or Wang needle biopsy under CT or bronchoscopic fluoroscopic guidance of enlarged contralateral N3 mediastinal nodes
- Contralateral mediastinal nodes >2 cm on CT scan
- Contralateral node positivity on PET scan
- Right sided primary with paralyzed left true vocal cord
Any of the following T4 lesions: Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, esophagus, vertebral body or carina:
- Written documentation of type of T4 extent by attending surgeon if the patient has had an exploratory thoracotomy or thoracoscopy
- T4 involvement of the trachea or carina by direct bronchoscopic visualization
- T4 involvement of the heart, esophagus, aorta, or vertebral body documented by CT scan, MRI or transesophageal ultrasound
- T4 involvement of the mediastinum may also be accepted by CT or MRI criteria if, in absence of the above organ involvement, there is a soft tissue extension directly into the mediastinal space.
- Radiographic criteria for involvement of main pulmonary artery or vein is allowed only if there is a mediastinal soft tissue mass.
- Age > 18 years
- ECOG performance status 0 or 1
- Ability to give informed consent
Adequate organ and marrow function as evidenced by the following peripheral blood counts or serum chemistries at study entry:
- WBC > 4,000/µL
- Absolute neutrophil count > 1,500/mm3
- Platelet count > 100 x 103 cells/mm3
- Bilirubin < 1.5 x institutional ULN
- AST or ALT < 2.5 x institutional ULN
- Alkaline Phosphatase <2.5 x institutional ULN
- Serum Creatinine < 2.0mg/dL and/or adequate creatinine clearance
- Adequate pulmonary function (FEV>1.5 liters, or if <1.5 liters, the predicted FEV1of the contralateral lung must be >800 cc based on the quantitative split function testing. (Predicted FEV1= FEV1 x % perfusion to uninvolved lung from quantitative lung V/Q scan report)
- Must have one measurable lesion by chest X-ray or CT scan. Lesion(s) must be accurately measured in at least one dimension (longest diameter to be recorded) as >20mm with conventional techniques or as >10mm with spiral CT scan
- Men and women of childbearing potential must agree to use effective contraception while on treatment and for 6 months after treatment
Exclusion Criteria:
- Malignant pleural or pericardial effusion
- Prior chemotherapy or radiation therapy
- Pregnant or lactating females
- Primary malignancy other than basal or squamous carcinoma of the skin or carcinoma in situ of the cervix, or any other cancer for which the patient has been disease free for five years. Other in situ malignancies (e.g. breast, bladder, etc) in the past 3 years are permissible
- Unintentional weight loss >10% body weight within the last 3 months
- Unable to provide informed consent
- Any pre-malignant myeloid condition or any malignancy with myeloid characteristics
- Active infection
- Known hypersensitivity to E. coli-derived proteins, pegfilgrastim, Filgrastim, or any other component of the product
- Significant nonmalignant disease including: documented HIV infection; uncontrolled heart disease, and poorly controlled diabetes
- Treatment within the last 30 days with any experimental agent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Annen: ARM 1
Cisplatin 75 mg/m2 day 1 and 22 Etoposide 80mg/m2 days 1-3, 22-24 Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days) Filgrastim 5µg/kg* SQ injection days 4-13 and days 25-34 Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles Pegfilgrastim 6 mg SQ injection day 2 of each cycle |
Cisplatin 75 mg/m2 day 1 and 22 Etoposide 80mg/m2 days 1-3, 22-24 Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days) Filgrastim 5µg/kg* SQ injection days 4-13 and days 25-34 Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles Pegfilgrastim 6 mg SQ injection day 2 of each cycle |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
To determine the safety and efficacy of administering pegfilgrastim with concurrent chemoradiotherapy and the potential benefit of administering pegfilgramstim with consolidation chemotherapy in patients with unresectable locally advanced NSCLC patients.
Tidsramme: One year
|
One year
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
To determine the frequency of dose reductions, dose delays, and dose omissions during chemoradiotherapy with filgrastim and consolidation therapy with pegfilgrastim.
Tidsramme: One year
|
One year
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Rogerio Lilenbaum, MD, Icahn School of Medicine at Mount Sinai
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i luftveiene
- Neoplasmer
- Lungesykdommer
- Neoplasmer etter nettsted
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Karsinom, bronkogent
- Bronkiale neoplasmer
- Lungeneoplasmer
- Karsinom, ikke-småcellet lunge
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Antineoplastiske midler
- Tubulin modulatorer
- Antimitotiske midler
- Mitosemodulatorer
- Antineoplastiske midler, fytogene
- Topoisomerase II-hemmere
- Topoisomerasehemmere
- Docetaxel
- Etoposid
- Cisplatin
Andre studie-ID-numre
- LUN 07
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Unresectable Locally Advanced NSCLC
-
Fundación de investigación HMSyntax for Science, S.LFullførtLocally Advanced Rectal Cancer (LARC)Spania
-
Yongchang ZhangRekrutteringHER2 Insertion Mutation Positive Advanced NSCLCKina
-
Astellas Pharma Global Development, Inc.TilgjengeligMetastatisk Gastroøsofageal Junction (GEJ) Adenocarcinoma | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer | Lokalt avansert ikke-opererbar gastrisk adenokarsinomkreft | Metastatisk gastrisk adenokarsinomkreftForente stater
-
AmgenAktiv, ikke rekrutterendeKRAS p, G12c Mutated /Advanced Metastatic NSCLCFinland, Forente stater, Canada, Belgia, Spania, Korea, Republikken, Nederland, Storbritannia, Australia, Danmark, Ungarn, Sverige, Taiwan, Hellas, Den russiske føderasjonen, Sveits, Frankrike, Italia, Japan, Polen, Brasil, Tyskland, ...
Kliniske studier på Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta
-
University of Michigan Rogel Cancer CenterNational Institutes of Health (NIH)Aktiv, ikke rekrutterendePlateepitelkarsinom i hode og nakkeForente stater
-
Southwest Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC... og andre samarbeidspartnereFullført
-
Tianjin Medical University Cancer Institute and...Ukjent
-
Eli Lilly and CompanyFullførtIkke-småcellet lungekreftForente stater, Argentina, Kina, Korea, Republikken
-
Nasser Hanna, M.D.Sanofi; Walther Cancer InstituteFullførtIkke-småcellet lungekreftForente stater
-
National Cancer Institute (NCI)FullførtStadium IIIA Ikke-småcellet lungekreft | Stadium IIIB Ikke-småcellet lungekreft | Plateepitel lungekreft | Adenokarsinom i lungen | Bronkoalveolær celle lungekreft | Storcellet lungekreftForente stater
-
M.D. Anderson Cancer CenterFullført
-
National Cancer Institute (NCI)AvsluttetStadium IIIA Ikke-småcellet lungekreft | Stadium IIIB Ikke-småcellet lungekreft | Plateepitel lungekreft | Adenokarsinom i lungen | Bronkoalveolær celle lungekreft | Storcellet lungekreftForente stater
-
Shanghai Chest HospitalUkjentNSCLC | SBRT | GM-CSFKina
-
American College of Radiology Imaging NetworkNational Cancer Institute (NCI); Radiation Therapy Oncology GroupUkjentLungekreftForente stater, Canada, Korea, Republikken